US Patent

US9670163 — Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2026-12-28 · 1y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects solid state forms of the compound N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.

USPTO Abstract

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2376 — Kalydeco
U-3606 — Kalydeco
U-2530 — Kalydeco
U-1911 — Kalydeco
U-4078 —
U-4078 —
U-4080 —
U-1311 — Kalydeco
U-2246 — Kalydeco
U-2376 — Kalydeco
U-1911 — Kalydeco
U-1311 — Kalydeco
U-3606 — Kalydeco
U-4068 —
U-4080 —
U-3429 — Kalydeco
U-1311 — Kalydeco
U-2246 — Kalydeco
U-4068 —

Patent Metadata

Patent number
US9670163
Jurisdiction
US
Classification
Method of Use
Expires
2026-12-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.